Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia - Report - MDSpire

Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia

  • By

  • Ondřej Fiala

  • Michaela Tkadlecová

  • Tomas Buchler

  • Jindřich Kopecký

  • Zuzana Tomčová

  • Michal Vočka

  • Zuzana Syčová-Milá

  • Hana Študentová

  • Martin Matějů

  • Alexander Savka

  • Eva Šlachtová

  • Peter Priester

  • Jan Králíček

  • Martina Spisarová

  • Anežka Zemánková

  • Radka Lohynská

  • Lucie Grmelová

  • Jana Obertová

  • Petr Stránský

  • Bohuslav Melichar

  • Alexandr Poprach

  • Patrik Palacka

  • June 30, 2026

  • 0 min

Share

Clinical Report: Nivolumab for Metastatic Renal Cell Carcinoma After Prior Treatment

Overview

This study evaluates the real-world effectiveness of nivolumab monotherapy in patients with metastatic renal cell carcinoma (mRCC) who have undergone prior treatment. Findings indicate a median overall survival of 24.2 months and a median progression-free survival of 8.6 months, with manageable toxicity.

Background

Nivolumab, an immune checkpoint inhibitor, is a key treatment option for mRCC, particularly in patients who have received prior therapies. Real-world data from Central and Eastern Europe are limited.

Data Highlights

OutcomeValue
Median Overall Survival (OS)24.2 months
Median Progression-Free Survival (PFS)8.6 months
Objective Response Rate (ORR)28.8%
Disease Control Rate (DCR)61.2%
Grade 3/4 Adverse Events11.4%

Key Findings

  • Median overall survival (OS) was 24.2 months.
  • Median progression-free survival (PFS) was 8.6 months.
  • Objective response rate (ORR) was 28.8% in the response-evaluable population.
  • Disease control rate (DCR) was 61.2%.
  • Grade 3/4 adverse events occurred in 11.4% of patients.
  • Higher baseline NLR and PLR were associated with inferior survival outcomes.

Clinical Implications

The study presents outcomes for nivolumab monotherapy in previously treated mRCC patients.

Conclusion

Nivolumab shows effective survival outcomes and manageable toxicity in real-world settings.

Related Resources & Content

  1. Motzer, R.J., et al., NEJM, 2015 -- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
  2. Motzer, R.J., et al., Cancer, 2020 -- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
  3. EAU Guidelines on Renal Cell Carcinoma, 2025
  4. ASCO Guideline, 2022 -- Management of Metastatic Clear Cell Renal Cell Carcinoma
  5. The ASCO Post — Nivolumab in Previously Treated Metastatic Renal Cell Cancer
  6. The ASCO Post — Nivolumab in Advanced Renal Cell Carcinoma After Antiangiogenic Therapy
  7. The ASCO Post — Nivolumab in Previously Treated Metastatic Renal Cell Cancer Related Articles
  8. The ASCO Post — Changing Landscape in the Treatment of Metastatic Renal Cell Carcinoma: Findings With Nivolumab and Cabozantinib
  9. Nivolumab in Previously Treated Metastatic Renal Cell Cancer
  10. Changing Landscape in the Treatment of Metastatic Renal Cell Carcinoma
  11. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Renal-Cell-Carcinoma-2025_2025-04-17-105637_dkgm.pdf
  12. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline | Journal of Clinical Oncology
  13. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - ScienceDirect
  14. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | New England Journal of Medicine
  15. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial - Motzer - 2020 - Cancer - Wiley Online Library
  16. Atezolizumab plus cabozantinib versus cabozantinib for patients with renal cell carcinoma after progression with prior immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomized, open-label, phase 3 trial - PMC
  17. FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma - PMC
  18. 42 Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma: Subgroup analysis of the phase 3 LITESPARK-005 study - PMC
  19. Management of Metastatic Renal Cell Carcinoma Following First-Line Immune Checkpoint Therapy Failure: A Systematic Review - PMC

Original Source(s)

Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia

  • by Ondřej Fiala, Michaela Tkadlecová, Tomas Buchler, Jindřich Kopecký, Zuzana Tomčová, Michal Vočka, Zuzana Syčová-Milá, Hana Študentová, Martin Matějů, Alexander Savka, Eva Šlachtová, Peter Priester, Jan Králíček, Martina Spisarová, Anežka Zemánková, Radka Lohynská, Lucie Grmelová, Jana Obertová, Petr Stránský, Bohuslav Melichar, Alexandr Poprach, Patrik Palacka

  • June 30, 2026

Related Content